Abbott Laboratories
In December of 2004, we acquired an exclusive worldwide license (excluding Japan) from Abbott Laboratories to develop and commercialize cethromycin. Cethromycin is a novel ketolide antibiotic in Phase III clinical development for the treatment of community acquired pneumonia and other respiratory tract infections.